38677-81-5 Usage
Originator
Exirel ,Pfizer Taito ,Japan,1982
Uses
Different sources of media describe the Uses of 38677-81-5 differently. You can refer to the following data:
1. Bronchodilator.
2. This relatively selective β2-adrenergic receptor agonist is structurally very similar to
albuterol, and it displays similar broncholytic properties. It is used as an inhaled drug for
treating bronchial asthma.
Manufacturing Process
To 78 ml of a 1 M solution of diborane in tetrahydrofuran under nitrogen and cooled to 0°C is added dropwise over a period of 40 minutes 13.5 g of N-tertbutyl-2-(5-benzyloxy-6-hydroxymethyl-2-pyridyl)-2-hydroxyacetamide in 250 ml of the same solvent. The reaction mixture is allowed to stir at room temperature for 3.5 hours, and is then heated to reflux for 30 minutes and cooled to room temperature. Hydrogen chloride (70 ml, 1.34 N) in ethanol is added dropwise, followed by the addition of 300 ml of ether. The mixture is allowed to stir for 1 hour and is then filtered, yielding 11.0 g, melting point 202°C (dec.). The hydrochloride dissolved in water is treated with a sodium hydroxide solution to pH 11 and is extracted into chloroform (2 x 250 ml). The chloroform layer is dried over sodium sulfate, concentrated to dryness in vacuo, and the residue recrystallized from isopropyl ether, 3.78 g, melting point 81°C to 83.5°C.A solution of 1.7 g of 2-hydroxymethyl-3-benzyloxy-(1-hydroxy-2-tert-butylaminoethyl)pyridine in 30 ml of methanol containing 1.2 ml of water is shaken with 700 mg of 5% palladiumon-charcoal in an atmosphere of hydrogen at atmospheric pressure. In 17 minutes the theoretical amount of hydrogen has been consumed and the catalyst is filtered. Concentration of the filtrate under reduced pressure provides 1.4 g of the crude product as an oil. Ethanol (5 ml) is added to the residual oil followed by 6 ml of 1.75 N ethanolic hydrogen chloride solution and, finally, by 5 ml of isopropyl ether. The precipitated product is filtered and washed with isopropyl ether containing 20% ethanol, 1.35 g, melting point 182°C (dec.).
Brand name
Maxair (3M Pharmaceuticals).
Therapeutic Function
Bronchodilator
Synthesis
Pirbuterol, α(6)–[[[1,1-dimethylethyl]amino]methyl]-3-hydroxy-2,6-pyridindimethanol
(23.3.22), is synthesized from 3-hydroxypyridine, which undergoes subsequent
hydroxymethylation and further alkylation by benzylchloride at the aromatic
hydroxyl group, giving 3-benzyloxy-2,6-bis-(hydroxymethyl)pyridine (23.3.17). Selective
oxidation of the 6-hydroxymethyl group using manganese peroxide gives 3-benzyloxy-2-
hydroxymethylpiperidine-6-aldehyde (23.3.18). Condensation of this with nitromethane
gives the corresponding nitromethylcarbinol 23.3.19, the nitro group of which is reduced
to an amine group by hydrogen using Raney nickel as a catalyst, which forms an aminoalcohol
23.3.20. Alkylation of the aminogroup with tert-butylbromide gives a secondary
amine (23.3.21), and removing the protective benzyl group by hydrogen reduction forms
pirbuterol (23.3.22) .
Check Digit Verification of cas no
The CAS Registry Mumber 38677-81-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,6,7 and 7 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 38677-81:
(7*3)+(6*8)+(5*6)+(4*7)+(3*7)+(2*8)+(1*1)=165
165 % 10 = 5
So 38677-81-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
38677-81-5Relevant articles and documents
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.
2-Phenyl-6-(1-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin maleate and its use as an intermediate
-
, (2008/06/13)
The maleic acid salt of 2-phenyl-6-(1-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin, its preparation and use as an intermediate for making 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-t-butylaminoethyl)pyridine, an effective bronchodilator.
